Effects of Vaccination and Previous Infection on Omicron Infections in Children

Dan-Yu Lin et al.

On October 29, 2021, the Food and Drug Administration authorized the BNT162b2 vaccine (Pfizer–BioNTech) for emergency use in children 5 to 11 years of age, on the basis of an immunobridging study and a small efficacy study.1 Recent case–control studies have shown modest short-term effectiveness of the BNT162b2 vaccine in this age group during the early phase of the period when the B.1.1.529 (omicron) vari- ant of severe acute respiratory syndrome corona- virus 2 (SARS-CoV-2) was spreading (from mid- December 2021 to mid-February 2022).2-4 We conducted a large cohort study over a 6 month period when the omicron variant was dominant. Here, we report on the protection conferred by the BNT162b2 vaccine and by previous SARS- CoV-2 infection against infection and coronavirus disease 2019 (Covid-19)–related hospitalization and death in children 5 to 11 years of age.

Latest articles

Rebecca Park Totilo Essential Oils for radiation sickness, biological warfare, chemical warfare...
Rebecca Park Totilo Living Grand Convention that inflammation is a signal that...
Maharishi Ayurveda Products International, Inc. Radiation—energy that travels through the atmosphere as...
Alan V. Schmukler There are numerous substances which are rumored to offer...
World Health Organization This document describes protocols and practices for ensuring the...

Thank you!

Thank you for your membership application. As soon as your payment has been received your membership will be activated and you will be informed via email.

Thank you.

Thank you!

The form has been submitted successfully!